By Angus Liu
After a call from Pfizer CEO Albert Bourla to Biohaven's chief exec Vlad Coric, Pfizer and Biohaven quickly came to terms on the buyout, reviving a plan Biohaven had explored years ago.
read more
By Annalee Armstrong
It’s a tough time for biotech. A market correction underway. Layoffs have beset the sector. And funding as well as M&A are down across the board. But that doesn’t mean there isn’t plenty going on in labs around the country. We recap the top biotech hubs across the U.S.
read more
Sponsored By: Parexel
The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics.
read more
By Annalee Armstrong
More than 70 women in biotech are lending their voices to the outcry of opposition to the Supreme Court’s decision to strike down Roe v. Wade, casting reproductive rights for women and pregnant people into doubt around the nation.
read more
By Andrea Park
True to its name, Orchestra BioMed is conducting a symphony of several business ventures at once.
read more
By Anastassia Gliadkovskaya
The country celebrated Pride during the month of June as numerous regulations were proposed or passed striking down access to lifesaving care, from abortion to hormone therapy. As the LGBTQ+ community faces persistent barriers and new threats to healthcare access, some industry leaders tout progress with the expansion of virtual care and more support for fertility care and family building.
read more
By Zoey Becker
GSK's consumer health spinoff will launch on July 18 with more than a portfolio of popular products. The company will have 10.3 billion pounds of debt under its belt upon launch, according to a report.
read more
By Conor Hale
To tackle the major risk factors of heart attacks and stroke, Novartis' U.K. division is teaming up with Medtronic, RYSE Asset Management and the Chelsea and Westminster Hospital NHS Foundation Trust.
read more
By Max Bayer
Vertex is restarting the engine of the phase 1/2 trial of its Type 1 diabetes med after the FDA lifted a clinical hold placed in May. The trial was originally paused after the agency said it didn't have enough evidence to support dose escalation.
read more
By Kevin Dunleavy
On Tuesday, the FDA took the unusual step of announcing a second advisory committee meeting to discuss the merits and risks of Amylyx's amyotrophic lateral sclerosis drug AMX0035. The meeting is set for September 7, three weeks before an approval decision is due.
read more
By Cameron Evans
The prioritization technology identifies opportunities at the individual level and from there, determines personalized steps for users.
read more
By Andrea Park
Amid a rocky few months for Ra Medical Systems, the devicemaker has notched a small win, courtesy of the FDA.
read more
By James Waldron
Cannabis has long been used as a form of self-medication, but what happens when use of that drug requires medication itself? Anebulo Pharmaceuticals hopes to be the first to answer that, as the biotech unveils positive phase 2 data for its treatment of acute cannabinoid intoxication.
read more
Sponsored by: Cognizant
Explore how Cognizant SIP helped Roche streamline its global feasibility process.
Sponsored by: Blue Matter Consulting
For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed.
Sponsored by: CG Life
Explore the new cell therapy handbook from Thermo Fisher Scientific.
Sponsored by: Catalent
What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?
Sponsored by: Thermo Fisher Scientific
Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals.
Sponsored by: Catalent
Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.
Sponsored by: Catalent
What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
